Katherine T Dawson

US Patent:

20130295169, Nov 7, 2013

Filed:

Mar 14, 2013

Appl. No.:

13/827228

Inventors:

Biogen Idec MA Inc. - , US
Katherine Dawson - Westwood MA, US
Ajay Nirula - Westlake Village CA, US

International Classification:

A61K 31/225
A61K 9/48
A61K 31/616
A61K 9/20

US Classification:

424451, 514547, 424465, 424489, 514163

Abstract:

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

US Patent:

20130287732, Oct 31, 2013

Filed:

Mar 25, 2013

Appl. No.:

13/850240

Inventors:

Katherine Dawson - Westwood MA, US
Ralf Linker - Bochum, DE
Ralf Gold - Bochum, DE

International Classification:

A61K 31/225
A61K 38/21
A61K 38/02

US Classification:

424 856, 514 179

Abstract:

Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I:wherein Rand Rare independently selected from OH, O, and (C)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

US Patent:

20200222354, Jul 16, 2020

Filed:

Mar 23, 2020

Appl. No.:

16/826938

Inventors:

- Cambridge MA, US
Katherine Dawson - Westwood MA, US
Ajay Nirula - Westlake Village CA, US

Assignee:

Biogen MA Inc. - Cambridge MA

International Classification:

A61K 31/225
A61K 31/60
A61K 45/06
A61K 9/20
A61K 9/28
A61K 31/616
A61K 9/48
A61K 9/16

Abstract:

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

US Patent:

20190358190, Nov 28, 2019

Filed:

Aug 5, 2019

Appl. No.:

16/532155

Inventors:

- Cambridge MA, US
Katherine Dawson - Westwood MA, US
Ajay Nirula - Westlake Village CA, US

Assignee:

Biogen MA Inc. - Cambridge MA

International Classification:

A61K 31/225
A61K 9/28
A61K 9/20
A61K 9/48
A61K 31/60
A61K 9/16
A61K 45/06
A61K 31/616

Abstract:

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

US Patent:

20180263946, Sep 20, 2018

Filed:

May 24, 2018

Appl. No.:

15/988568

Inventors:

- Cambridge MA, US
Katherine Dawson - Westwood MA, US
Ajay Nirula - Westlake Village CA, US

Assignee:

Biogen MA Inc. - Cambridge MA

International Classification:

A61K 31/225
A61K 45/06
A61K 31/60
A61K 9/28
A61K 9/20
A61K 9/48
A61K 31/616
A61K 9/16

Abstract:

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

US Patent:

20180185319, Jul 5, 2018

Filed:

Mar 2, 2018

Appl. No.:

15/910745

Inventors:

- Cambridge MA, US
Katherine Dawson - Westwood MA, US
Ajay Nirula - Westlake Village CA, US

International Classification:

A61K 31/225
A61K 45/06
A61K 31/60
A61K 9/28
A61K 9/20
A61K 9/48
A61K 9/16
A61K 31/616

Abstract:

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

US Patent:

20180021288, Jan 25, 2018

Filed:

Jul 7, 2017

Appl. No.:

15/644029

Inventors:

- Cambridge MA, US
Katherine Dawson - Westwood MA, US
Ralf Linker - Bochum, DE
Ralf Gold - Bochum, DE

Assignee:

Biogen MA Inc. - Cambridge MA

International Classification:

A61K 31/225
A61K 31/194
A61K 9/28
A61K 31/785
A61K 38/02
A61K 9/48
A61K 38/21
A61K 9/20

Abstract:

Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I:wherein Rand Rare independently selected from OH, O, and (C)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

US Patent:

20160250172, Sep 1, 2016

Filed:

Mar 1, 2016

Appl. No.:

15/057836

Inventors:

- Cambridge MA, US
Katherine Dawson - Westwood MA, US
Ralf Linker - Bochum, DE
Ralf Gold - Bochum, DE

International Classification:

A61K 31/225
A61K 31/785
A61K 31/194

Abstract:

Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I:wherein Rand Rare independently selected from OH, O, and (C)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.